Rejuvenation Technologies Inc.
Mountain View, CA Doing business as Rejuvenation Technologies Inc. 1969
- UEI
- T6RGDB42JZN6
- CAGE
- 7QZ85
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 415 Clyde Ave Unit 107, Mountain View, CA 94043, USA
- Website
- rejuvenationtech.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Rejuvenation Technologies Inc.
Rejuvenation Technologies Inc. (RTI) is a for-profit biotechnology company focused on developing advanced therapeutic technologies targeting cellular regeneration and disease intervention through innovative mRNA and lipid nanoparticle (LNP) delivery systems. Registered in SAM.gov since October 2016, the company specializes in developing cutting-edge therapeutic approaches that aim to extend telomeres and enhance the regenerative capacity of progenitor cells, with a particular emphasis on addressing age-related and degenerative diseases. Their core technology involves creating lipid nanoparticle delivery vehicles capable of efficiently transporting modified mRNA encoding telomerase (TERT) to specific cell types, potentially reversing cellular aging processes and mitigating disease progression.
The company has secured multiple significant federal grant awards from civilian agencies, predominantly focusing on translational research in regenerative medicine. These grants, totaling over $1.4 million, have been awarded by agencies such as the National Institute of General Medical Sciences, the National Center for Advancing Translational Sciences, the National Heart Lung and Blood Institute, and the National Institute on Alcohol Abuse and Alcoholism. RTI's grant-funded research has concentrated on developing mRNA therapies targeting specific medical conditions, including pulmonary fibrosis, alcoholic hepatitis, and liver disease. Their research aims to create advanced tools for intravenously-infused RNA lipid nanoparticle therapeutics, with specific objectives including developing high-sensitivity drug analytics, conducting biodistribution studies, evaluating drug component stability, and creating bioanalytical methods to support clinical translation of their innovative mRNA therapies. The company's work demonstrates a sophisticated approach to addressing complex medical challenges through targeted cellular regeneration technologies.
Quick answers
What is Rejuvenation Technologies Inc.'s UEI?
Rejuvenation Technologies Inc.'s Unique Entity ID (UEI) in SAM.gov is T6RGDB42JZN6.
What is Rejuvenation Technologies Inc.'s CAGE code?
Rejuvenation Technologies Inc.'s CAGE code is 7QZ85.
What is Rejuvenation Technologies Inc.'s primary NAICS code?
Rejuvenation Technologies Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Rejuvenation Technologies Inc. located?
Rejuvenation Technologies Inc.'s physical address in SAM.gov is 415 Clyde Ave Unit 107, Mountain View, CA 94043, USA.
Is Rejuvenation Technologies Inc. registered in SAM.gov?
Yes. Rejuvenation Technologies Inc.'s SAM.gov registration is active through August 17, 2027.
What is Rejuvenation Technologies Inc.'s most recent federal award?
Rejuvenation Technologies Inc.'s most recent federal grant award is Advancing a telomere extension biologic to treat alcohol-associated liver damage to IND - abstract rejuvenation… (SB1AA033292), from National Institute on Alcohol Abuse and Alcoholism, on July 1, 2026.
On GovTribe
See Rejuvenation Technologies Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors